The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The use of early ALC after BCMA CAR-T as a surrogate for CAR-T expansion, response & PFS in myeloma
Mark Bustoros, MD, Weill Cornell Medicine, New York City, NY, discusses a multi-institutional study exploring the role of absolute lymphocyte count (ALC) as a biomarker of response and progression-free survival (PFS) in patients with relapsed/refractory (R/R) multiple myeloma who received BCMA-directed CAR-T therapy. Findings reveal that an ALC spike within 15 days post-infusion is a positive indicator of clinical response to both idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), with high ALC correlating with deeper responses and longer PFS. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
